3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
3
Neoplasms
3
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemangioma
2
Carcinoma, Non-Small-Cell Lung
2
Radiation Pneumonitis
1
Radiation Injuries
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Lung Diseases, Interstitial
1
Leukemia, Hairy Cell
1
Leukemia
1
Hepatitis
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Dendritic Cell Sarcoma, Interdigitating
1
Chemical and Drug Induced Liver Injury
1
Bulbo-Spinal Atrophy, X-Linked
1
Brain Neoplasms
1
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Adrenal Cortex Hormones
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled